Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $7.12, for a total value of $81,502.64. Following the sale, the director now directly owns 7,132,769 shares in the company, valued at $50,785,315.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.82, for a total transaction of $78,068.54.
• On Tuesday, July 23rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.48, for a total transaction of $97,070.56.
• On Tuesday, July 9th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04.
• On Tuesday, June 25th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total transaction of $108,860.97.
• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $7.81 on Friday. The stock has a market capitalization of $1.86 billion, a PE ratio of -4.88 and a beta of 0.83. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The company has a 50 day moving average price of $7.76 and a 200 day moving average price of $9.14. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same period last year, the company earned ($0.38) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $128,041,000. Gladstone Institutional Advisory LLC acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth $133,000. Capstone Investment Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $161,000. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $34,825,000. Finally, UBS Group AG grew its stake in shares of Recursion Pharmaceuticals by 101.9% during the fourth quarter. UBS Group AG now owns 691,911 shares of the company’s stock worth $6,822,000 after purchasing an additional 349,232 shares during the period. 89.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on RXRX. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.